Regeneron Pharmaceuticals

Open: 783.91 Close: 791.27 Change: 7.36

The 16 top things that an AI found about Regeneron Pharmaceuticals Stock... they will surprise you

This document will help you to evaluate Regeneron Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, earnings, price, Inc, REGN, drop, …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc (REGN) stock is trading at $792.76 as of 3:14 PM on Thursday, Oct 26, a drop of -4.28, or -0.54% from the previous closing price $797.04. The current share price is $791.27 USD today.

Today's News

Regeneron Pharmaceuticals (NASDAQ:REGN) has made for a fantastic growth story over the years. Recent FDA Approval could give Regenerons Top Line a Big Boost September 20th, 2023 - Motley Fool. Regeneron Pharmaceuticals Inc (REGN) stock is trading at $792.76 as of 3:14 PM on Thursday, Oct 26, a drop of -4.28, or -0.54% from the previous closing price $797.04. The current share price is $791.27 USD today. The Score for REGN is 56, which is 12% above the historic median of 50 asymmatters acknowledgemonkey Rome redirected Everyoneiosisoa bogepend Regeneron Pharmaceuticals ( NASDAQ: REGN) is scheduled to announce Q3 earnings results on Thursday, November 2nd, before market open. Q4 earnings are confirmed for February 2, 2024. There is no upcoming split for Regeneron. Pfizer posts reported net loss of $2.38bn for Q3 2023. AbbVie posts drop in Q32023 attributable net earnings. FDA warns of infection risks from over-the-counter eye drops. Regeneron Pharmaceuticals Inc.s market capitalization is $84.25 B by 106.74 M shares outstanding. The high in the last 52 weeks of Regeneron. Pharmaceuticals stock has received a consensus rating of buy. Regeneron Pharmaceuticals Inc expected to post earnings of $10.76 a share - earnings preview. Wall Streets median 12-month price target for Regeneron pharmaceuticals Inc is $910​, above​ its last closing price.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

The game is changing. There is a new strategy to evaluate Regeneron Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, earnings, price, Inc, REGN, drop, and the most common words in the summary are: regeneron, pharmaceutical, stock, market, job, price, news, . One of the sentences in the summary was: The current share price is $791.27 USD today.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #stock #market #job #price #news.